Literature DB >> 18328931

Liver cirrhosis.

Detlef Schuppan1, Nezam H Afdhal.   

Abstract

Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, which leads to portal hypertension and end-stage liver disease. Recent advances in the understanding of the natural history and pathophysiology of cirrhosis, and in treatment of its complications, have resulted in improved management, quality of life, and life expectancy of patients. Liver transplantation remains the only curative option for a selected group of patients, but pharmacological treatments that can halt progression to decompensated cirrhosis or even reverse cirrhosis are currently being developed. This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments.

Entities:  

Mesh:

Year:  2008        PMID: 18328931      PMCID: PMC2271178          DOI: 10.1016/S0140-6736(08)60383-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  144 in total

1.  Portopulmonary hypertension: an increasingly important complication of cirrhosis.

Authors:  Laurie Blendis; Florence Wong
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

Review 2.  Evidence-based evolution of the MELD/PELD liver allocation policy.

Authors:  Russell H Wiesner
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

3.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

Authors:  Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

4.  Cause and composition of foetor hepaticus.

Authors:  A Tangerman; M T Meuwese-Arends; J B Jansen
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

5.  HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.

Authors:  Andreas Erhardt; Andrea Maschner-Olberg; Claudia Mellenthin; Günther Kappert; Ortwin Adams; Andreas Donner; Reinhard Willers; Claus Niederau; Dieter Häussinger
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

6.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

7.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

Review 8.  Diagnosis and treatment of portal hypertension.

Authors:  R de Franchis; A Dell'Era; F Iannuzzi
Journal:  Dig Liver Dis       Date:  2004-12       Impact factor: 4.088

9.  Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease.

Authors:  K Yoshizawa; M Ota; S Saito; A Maruyama; T Yamaura; A Rokuhara; K Orii; T Ichijo; A Matsumoto; E Tanaka; K Kiyosawa
Journal:  Tissue Antigens       Date:  2003-02

10.  Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Authors:  Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

View more
  606 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Trans-radial versus trans-femoral access in patients with end-stage liver disease undergoing cardiac catheterization.

Authors:  Kent Feng; Vipul Gupta; Enrique Terrazas; Yerem Yeghiazarians; Thomas Ports; Gabriel Gregoratos; Mehdi Tavakol; John Paul Roberts; Andrew Boyle
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

3.  ¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis.

Authors:  Su-Wen Qi; Zhi-Guang Tu; Wu-Jian Peng; Lin-Xian Wang; Xin Ou-Yang; An-Ji Cai; Yong Dai
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

Review 4.  Accuracy of ultrasound to identify chronic liver disease.

Authors:  Richard Allan; Kerry Thoirs; Maureen Phillips
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

Review 5.  Embryonic and induced pluripotent stem cells as a model for liver disease.

Authors:  Hiroshi Yagi; Edgar Tafaleng; Masaki Nagaya; Marc C Hansel; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Crit Rev Biomed Eng       Date:  2009

6.  A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.

Authors:  Taichiro Nishikawa; Nadège Bellance; Aaron Damm; Han Bing; Zhen Zhu; Kan Handa; Mladen I Yovchev; Vasudha Sehgal; Tyler J Moss; Michael Oertel; Prahlad T Ram; Iraklis I Pipinos; Alejandro Soto-Gutierrez; Ira J Fox; Deepak Nagrath
Journal:  J Hepatol       Date:  2014-02-26       Impact factor: 25.083

7.  Decompensated cirrhosis and microbiome interpretation.

Authors:  Jasmohan S Bajaj; Naga S Betrapally; Patrick M Gillevet
Journal:  Nature       Date:  2015-09-17       Impact factor: 49.962

8.  Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases.

Authors:  Wei Zhang; Fan Wang; Hong Wang; Bingzhu Hua; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

9.  Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.

Authors:  Dalia Omran; Ayman Yosry; Samar K Darweesh; Mohammed M Nabeel; Mohammed El-Beshlawey; Sameh Saif; Azza Fared; Mohamed Hassany; Rania A Zayed
Journal:  Clin Exp Med       Date:  2017-05-31       Impact factor: 3.984

Review 10.  Non-invasive diagnosis of advanced fibrosis and cirrhosis.

Authors:  Suraj Sharma; Korosh Khalili; Geoffrey Christopher Nguyen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.